Company intelligence / Profile preview

The Medicine Accelerator

Ownership: Private
Development stage: Other

Overview

The company has demonstrated significant acceleration in CMC timelines—reducing time-to-patient by up to two years and dramatically lowering cost-per-dose for advanced therapeutics. Over 35 active programs are supported on their digital platform across major therapeutic areas.

Therapeutic areas: OncologyPulmonologyNeurologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)Proteins/biologicsAdvanced therapeutics (likely includes small molecules, peptides, etc.)
Industry: Drug Discovery Services

Partnerships

Eight of the top ten biopharma companies are customers or partners; specific names not disclosed publicly.Enterprise Ireland is noted as a supporter/investor in expansion plans.

Beyond the preview

Go deeper on The Medicine Accelerator.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Medicine Accelerator.

Explore the full profile